Global Clinical Trial Imaging Market Size by Product and Service, Modality, Application, End Users, Region and Forecast 2034
Overview
The Global Clinical Trial Imaging Market was valued at USD 1.56 Billion in 2025 and is projected to reach USD 3.14 Billion by 2034, growing at a CAGR of 8.1% during the forecast period 2026–2034.
| Parameter | Value |
|---|---|
| Market Size (2025) | USD 1.56 Billion |
| Market Size (2034) | USD 3.14 Billion |
| CAGR | 8.1% |
| Historical Period | 2020 to 2025 |
| Forecast Period | 2026 to 2034 |
Global Clinical Trial Imaging Market Overview
A clinical trial is a process of discovering new drugs. It is designed for giving medical treatment and to analyze its effects on humans. Imaging plays an important role in clinical trials and approx. 50 % of clinical trials needed imagining. Medical imaging is helpful in the drug development process because it provides efficacy evaluation and safety monitoring information that is required in clinical trials for regulatory submission.
Clinical Trial Imaging also provides insights into the drug mechanism of action (MOA) and drug effects, which can assist researchers in making scientifically sound decisions. The regulatory authority FDA has provided several guidance documents outlining the importance of imaging in clinical trials for cancer therapies as well as other indications.
Asia Pacific has become a hotspot for clinical trial activity and is expected to account for nearly half of all global clinical trial activity in 2025. Almost half of the clinical trial locations are located in the APAC region. It becomes important for manufacturers to provide the best possible treatment or therapy to the end user owing to the increased competition amongst pharmaceutical and biotechnology companies all over the world.
This factor is contributing to the development of clinical trials as a large number of novel drug discoveries are being done by these companies. Thus, the increasing number of biotechnology and pharmaceutical companies as well as Contract Research Organizations (CROs), the development of innovative imaging techniques, and rising R&D investment to develop new drugs and therapies are some of the key factors driving the global Clinical Trial Imaging market.
The Clinical Trial Imaging Market report forecasts revenue growth at global, and country levels and provides an analysis of the latest industry trends in each of the sub-segments during the forecast period. MMR has segmented the global Clinical Trial Imaging Market report based on Product and Service, Modality, End-User, and region. The report contains strategic profiling of top key players in the market, a wide-ranging analysis of their core competencies, and their strategies like new product launches, growths, agreements, joint ventures, partnerships, and acquisitions that apply to the businesses. Our team of analysts can also provide you with data in excel files and pivot tables or can assist you in creating presentations from the data sets available in the report.
Global Clinical Trial Imaging Market Growth Outlook
To know about the Research Methodology : Request Free Sample Report
Global Clinical Trial Imaging Market Key Insights
Clinical Trial Imaging Market Dynamics:
Increasing Oncology Clinical Trials and Demand for Accurate Diagnostic Imaging
The growing adoption of advanced diagnostic imaging technologies in oncology clinical trials is a major driver of the Global Clinical Trial Imaging Market. Pharmaceutical and biotechnology companies increasingly utilize Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Positron Emission Tomography (PET) to evaluate treatment efficacy, monitor disease progression, and assess therapeutic responses. The increasing use of RECIST 1.1 guidelines, which allow measurement of up to 5 target lesions, with a maximum of 2 lesions per organ, strengthens demand for standardized tumor assessment and independent imaging review services. Additionally, clinical research organizations integrate 1.5 Tesla and 3 Tesla MRI systems, advanced image analysis software, and centralized imaging services to improve image quality and clinical data consistency. Growing demand for precision medicine, oncology drug development, and imaging-based clinical endpoints supports the expansion of clinical trial imaging services across global pharmaceutical research programs.
High Imaging Equipment Costs and Expensive Clinical Trial Imaging Services
The high cost of advanced medical imaging equipment and specialized image interpretation services restrains the Clinical Trial Imaging Market Growth, particularly among small biotechnology companies and research institutions. Establishing clinical imaging infrastructure requires substantial investment in 3 Tesla MRI scanners, PET/CT systems, imaging analysis software, image storage platforms, and qualified radiology professionals. Clinical research facilities also incur recurring expenses associated with equipment calibration, imaging protocol development, image quality assurance, maintenance, and centralized radiology review. PET imaging services require radiotracer production and distribution infrastructure, while MRI-based clinical trial assessments depend on specialized scanning sequences and qualified technical personnel. The financial burden of conducting repeated imaging examinations across multiple clinical trial sites limits the adoption of advanced clinical trial imaging solutions among organizations operating with restricted research budgets.
Growing Adoption of Imaging Biomarkers and Precision Medicine Research
The increasing integration of quantitative imaging biomarkers into personalized medicine and targeted drug development creates significant opportunities in the Clinical Trial Imaging Market. Pharmaceutical manufacturers increasingly investigate PET imaging biomarkers, functional MRI, diffusion-weighted MRI, and molecular imaging technologies to identify biological responses and support patient selection during clinical research. Advanced 18F-FDG PET imaging, which uses a radiotracer with a physical half-life of approximately 110 minutes, supports metabolic activity assessment in oncology research and creates opportunities for specialized radiopharmaceutical imaging services. Additionally, imaging biomarker development, quantitative image analysis, and automated lesion segmentation solutions enable clinical research sponsors to investigate treatment responses beyond conventional anatomical measurements. Increasing investment in targeted therapies, neurological research, and precision oncology strengthens opportunities for clinical trial imaging software providers, imaging core laboratories, and specialized imaging contract research organizations.
Maintaining Imaging Data Consistency Across Multicenter Clinical Trials
Maintaining standardized image acquisition, interpretation, and data management across geographically distributed research facilities represents a major challenge for the Global Clinical Trial Imaging Industry. Multicenter clinical trials frequently involve different CT scanner configurations, MRI field strengths, imaging reconstruction methods, and radiology reporting practices, creating variations in image quality and quantitative measurements. Under RECIST 1.1, measurable solid tumor lesions generally require a minimum longest diameter of 10 mm, while pathological lymph nodes require a short-axis measurement of at least 15 mm, making accurate lesion identification essential for reliable clinical assessments. Differences in imaging equipment calibration, scanning protocols, patient positioning, and radiologist interpretation increase the complexity of centralized image review. Clinical trial imaging service providers must also manage secure DICOM image transfers, patient data protection, regulatory documentation, and imaging quality control across international research networks.
Global Clinical Trial Imaging Market Trends
Growing Adoption of Centralized Clinical Trial Imaging Services
1. Multicenter Imaging Data Collection – CT, MRI, PET, and Ultrasound
The increasing adoption of Multicenter Clinical Trial Imaging Services drives demand for CT, MRI, PET, and ultrasound imaging across pharmaceutical research. Clinical trial imaging CROs utilize 1.5T and 3T MRI scanners and advanced diagnostic imaging systems to support oncology clinical trials, disease monitoring, and treatment-response evaluation.
2. Standardized DICOM Transfer – Secure Medical Image Submission and Archiving
The growing integration of DICOM Imaging Standards supports secure medical image transmission, storage, and clinical imaging data management. Centralized imaging service providers utilize PACS, cloud-based imaging platforms, and standardized DICOM protocols to improve image interoperability and clinical trial data accessibility.
3. Central Imaging Quality Control – Imaging Protocol and Quality Verification
The increasing demand for Clinical Trial Imaging Quality Control Services supports standardized imaging protocols, scanner calibration, and medical image verification. Imaging CROs assess CT resolution, MRI scanning parameters, PET image quality, and imaging artifacts to maintain consistent clinical imaging datasets across research sites.
4. Independent Imaging Review – Centralized Radiology Assessment
The growing adoption of Blinded Independent Central Review (BICR) strengthens demand for independent radiology assessment and oncology imaging endpoint evaluation. Clinical trial imaging specialists utilize RECIST 1.1 criteria, including the general 10 mm minimum measurable non-nodal lesion diameter, to support standardized tumor response assessments.
5. Clinical Imaging Endpoint Database – Validated Imaging Measurements
The increasing integration of Clinical Imaging Endpoint Management Systems supports validated tumor measurements, imaging biomarker analysis, and treatment-response documentation. Centralized imaging databases utilize automated data verification, digital audit trails, and cloud-based clinical imaging software to strengthen clinical trial data accuracy and regulatory compliance.
Centralized Clinical Trial Imaging Services Workflow Funnel (2026)
Clinical Trial Imaging Market Segment Analysis:
Global Clinical Trial Imaging Market, by End User
The Clinical Trial Imaging Market by End User is segmented into Contract Development & Manufacturing Organizations (CDMOs), Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Medical Devices Manufacturers, and Others. Biotechnology and Pharmaceutical Companies represent a major end-user segment, driven by increasing demand for advanced clinical trial imaging services, oncology drug development, precision medicine, and imaging-based treatment response assessment. These companies increasingly utilize CT, MRI, PET, and ultrasound imaging technologies to support clinical research, drug efficacy evaluation, and imaging biomarker analysis. Contract Development & Manufacturing Organizations (CDMOs) support clinical development activities through partnerships with specialized imaging service providers, while Academic & Research Institutes utilize diagnostic imaging solutions for neurological research, oncology studies, and clinical investigations. Medical Devices Manufacturers integrate clinical imaging technologies into device validation, performance assessment, and regulatory clinical studies. Increasing adoption of AI-powered medical imaging, centralized imaging services, quantitative imaging biomarkers, and clinical trial imaging data management platforms strengthens demand across these end-user segments.
Global Clinical Trial Imaging Market, by Mobility
The Clinical Trial Imaging Market by Modality is divided into Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Ultrasound, Positron Emission Tomography (PET), X-Ray, Echocardiography, and Other Modalities. Magnetic Resonance Imaging (MRI) represents a significant segment due to its increasing application in oncology clinical trials, neurological drug development, and advanced soft tissue imaging. The growing adoption of 1.5 Tesla and 3 Tesla MRI scanners supports high-resolution anatomical imaging, disease progression monitoring, and quantitative imaging biomarker analysis. Computed Tomography (CT) plays an important role in tumor measurement, RECIST 1.1 response assessment, and oncology clinical trial imaging services, while Positron Emission Tomography (PET) supports molecular imaging, metabolic activity evaluation, and precision medicine research. Ultrasound Imaging provides real-time, non-invasive diagnostic assessment, whereas X-Ray Imaging supports skeletal examinations and medical device clinical studies. Echocardiography enables cardiac function monitoring, including left ventricular ejection fraction (LVEF) assessment, during cardiovascular and oncology clinical trials. Increasing integration of AI-powered medical imaging software, centralized imaging services, and clinical trial imaging data management platforms strengthens demand across imaging modalities in the Global Clinical Trial Imaging Market.
Global Clinical Trial Imaging Market Regional Insights
North America holds a prominent position in the Global Clinical Trial Imaging Market, supported by advanced healthcare infrastructure, increasing pharmaceutical research investments, and widespread adoption of diagnostic imaging technologies. The United States drives regional demand through extensive oncology clinical trials, biotechnology research, and the presence of established Clinical Trial Imaging Contract Research Organizations (CROs). Pharmaceutical companies increasingly utilize Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), and AI-powered medical imaging solutions for drug efficacy evaluation and imaging biomarker analysis. Growing adoption of Centralized Imaging Services, Blinded Independent Central Review (BICR), and Clinical Imaging Data Management Platforms strengthens regional clinical research capabilities.
Europe represents a significant market for Clinical Trial Imaging Services, supported by established pharmaceutical research networks, clinical imaging technology advancements, and increasing demand for standardized imaging protocols. Germany, the United Kingdom, France, and Switzerland contribute to regional growth through biotechnology research, oncology drug development, and clinical imaging infrastructure. The increasing integration of 3 Tesla MRI scanners, PET/CT imaging systems, quantitative imaging biomarkers, and cloud-based medical imaging platforms supports accurate clinical trial endpoint assessment. Growing emphasis on Good Clinical Practice (GCP), imaging data quality assurance, and independent radiology review strengthens the adoption of centralized clinical trial imaging solutions across European research institutions.
Asia Pacific exhibits strong growth potential in the Clinical Trial Imaging Market, driven by expanding pharmaceutical clinical trials, increasing biotechnology investments, and developing medical imaging infrastructure. China, India, Japan, South Korea, and Australia support regional demand through growing clinical research activities and healthcare technology adoption. The increasing utilization of MRI, CT, PET/CT, and Ultrasound Imaging Services strengthens oncology research, neurological drug development, and precision medicine applications. Growing adoption of AI-Powered Clinical Trial Imaging, Centralized Radiology Review, Imaging Biomarker Analysis, and Clinical Imaging CRO Services supports regional market expansion.
South America experiences increasing demand for Clinical Trial Imaging Services, supported by expanding pharmaceutical research activities, growing clinical trial investments, and improving diagnostic imaging infrastructure. Brazil, Argentina, Chile, and Colombia contribute to regional market development through oncology clinical trials, biotechnology research, and international pharmaceutical collaborations. The increasing adoption of Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), and Ultrasound Imaging Technologies supports disease monitoring, drug efficacy evaluation, and clinical imaging endpoint assessment. Growing integration of Centralized Clinical Trial Imaging Services, AI-Powered Medical Imaging, Independent Radiology Review, and Cloud-Based Clinical Imaging Data Management Platforms strengthens clinical research capabilities and supports the expansion of the South America Clinical Trial Imaging Market.
The Middle East & Africa region presents emerging opportunities in the Global Clinical Trial Imaging Market, supported by healthcare infrastructure development, increasing clinical research investments, and expanding access to advanced diagnostic imaging equipment. Saudi Arabia, the United Arab Emirates, and South Africa contribute to regional adoption of MRI, CT, PET/CT, and Molecular Imaging Technologies across oncology and cardiovascular clinical research. The increasing integration of Digital Clinical Trial Imaging Platforms, Cloud-Based Imaging Data Management, Centralized Imaging Services, and Independent Radiology Review Solutions supports multicenter clinical trials and strengthens regional clinical imaging capabilities.
Global Clinical Trial Imaging Market Recent Developments
| Date | Recent Developments |
|---|---|
| October 2026 | Perceptive Discovery and Nucleus Radio Pharma announce a strategic partnership to integrate preclinical molecular imaging, radiochemistry, and clinical-scale radiopharmaceutical manufacturing. The collaboration supports Molecular Imaging Services, Radiopharmaceutical Development, and Clinical Trial Imaging Applications. |
| September 2026 | Image Analysis Group (IAG) and Resonance Health announce a global strategic partnership combining the DYNAMIKA AI-powered clinical imaging platform with quantitative MRI biomarkers, FerriScan, and HepaFatScan technologies. The agreement expands Centralized Clinical Trial Imaging Services for obesity and metabolic disease research. |
| May 2026 | Image Analysis Group (IAG) and HeartcoR Solutions announce a strategic partnership integrating cardiac safety monitoring, ECG analysis, independent imaging review, and multimodality imaging core laboratory services. The collaboration strengthens Clinical Trial Imaging CRO Services and Cardiac Imaging Endpoint Assessment. |
| March 2026 | Thermo Fisher Scientific completes its acquisition of Clario Holdings for USD 8.875 billion in cash, plus potential additional payments. The acquisition expands its Clinical Trial Endpoint Data Management, Medical Imaging Solutions, and Clinical Research Technology Services. |
| February 2026 | Xing Imaging announces its selection as the imaging core laboratory for the Alzheimer's Tau Platform Phase II clinical trial, involving up to 750 participants across approximately 78 U.S. clinical sites. The agreement supports Tau PET Imaging, Neuroimaging Biomarker Analysis, and Centralized Clinical Trial Imaging Services. |
Global Clinical Trial Imaging Market Competitive Landscape
The Clinical Trial Imaging Market features strong competition among leading Clinical Trial Imaging Contract Research Organizations (CROs), medical imaging technology providers, and pharmaceutical clinical research service companies. Key players such as Clario, ICON plc, IQVIA, Medpace, Perceptive, and Image Analysis Group (IAG) focus on expanding centralized imaging services, independent radiology review, and advanced clinical imaging data management solutions. These companies integrate Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), and AI-powered medical imaging technologies to support oncology clinical trials, neurological research, and cardiovascular drug development.
Leading companies strengthen their competitive positions through strategic partnerships, mergers and acquisitions, technological innovation, and clinical imaging service expansion. Growing investment in AI-based image analysis software, quantitative imaging biomarkers, Blinded Independent Central Review (BICR), and cloud-based clinical trial imaging platforms supports service differentiation and operational efficiency. Market participants increasingly emphasize imaging protocol standardization, automated tumor measurement, regulatory compliance, and clinical imaging endpoint validation to address pharmaceutical and biotechnology research requirements, creating opportunities across the Global Clinical Trial Imaging Market.
Clinical Trial Imaging Market Scope: Inquire before buying
| Clinical Trial Imaging Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 1.56 USD Bn |
| Forecast Period 2026-2034 CAGR: | 8.1% | Market Size in 2034: | 3.14 USD Bn |
| Segments Covered: | by Product and Service | Trial Design Consulting Services Read Analysis Services Operational Imaging Services Imaging Software Others |
|
| by Modality | Magnetic Resonance Imaging Computed Tomography Ultrasound Positron Emission Tomography X-Ray Echocardiography Other Modalities |
||
| by Application | Nonalcoholic Steatohepatitis (NASH) Chronic Kidney Disease (CKD) Cardiovascular Diseases Ophthalmology Oncology Gastroenterology Pediatrics Others |
||
| by End Users | Contract Development & Manufacturing Organization Biotechnology and Pharmaceutical Companies Academic & Research Institutes Medical Devices Manufacturers Others |
||
Clinical Trial Imaging Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Clinical Trial Imaging Market key players
1. Clario
2. ICON plc
3. IQVIA Holdings Inc.
4. Medpace Holdings, Inc.
5. Parexel International Corporation
6. IXICO plc
7. Median Technologies
8. Imaging Endpoints
9. WorldCare Clinical
10. Voiant
11. Calyx
12. Image Analysis Group (IAG)
13. Invicro
14. Perspectum
15. Resonance Health Ltd.
16. Radiant Sage LLC
17. Intrinsic Imaging LLC
18. Navitas Life Sciences
19. WCG Clinical
20. Alimentiv Inc.
21. Biospective Inc.
22. Image Core Lab Pvt. Ltd.
23. Prism Clinical Imaging
24. ProScan Imaging
25. Medical Metrics Inc.
26. Cardiovascular Imaging Technologies LLC
27. Boston Imaging Core Lab LLC
28. Anagram 4 Clinical Trials
29. Micron Inc.
30. RadMD
31. Yunu Inc.
32. QMENTA
33. QUANTIFICARE
34. THIRONA
35. icometrix
36. Quibim
37. Mint Medical GmbH
38. Circle Cardiovascular Imaging
39. 4DMedical
40. Collective Minds Research
41. Signant Health
42. Medidata Solutions
43. Siemens Healthineers
44. GE HealthCare
45. Philips
46. Guerbet
47. Bracco Imaging
48. Bayer AG (Centafore)
49. Charles River Laboratories
50. Syneos Health
Frequently Asked Questions:
1. What is the Global Clinical Trial Imaging Market size in 2025?
The Global Clinical Trial Imaging Market is valued at USD 1.56 Billion in 2025, supported by increasing oncology clinical trials, pharmaceutical R&D investments, and advanced medical imaging services.
2. What is the Clinical Trial Imaging Market forecast for 2034?
The Clinical Trial Imaging Market is projected to reach USD 3.14 Billion by 2034, growing at a CAGR of 8.1% from 2026 to 2034.
3. What are the major drivers of Clinical Trial Imaging Market growth?
Key Clinical Trial Imaging Market growth drivers include increasing pharmaceutical research, oncology drug development, precision medicine adoption, and demand for MRI, CT, and PET imaging services.
4. Which modality is significant in the Clinical Trial Imaging Market?
Magnetic Resonance Imaging (MRI) represents a significant modality, supported by growing applications in oncology clinical trials, neurological research, and quantitative imaging biomarker analysis.
5. What are the key trends in the Global Clinical Trial Imaging Market?
Major Clinical Trial Imaging Market trends include AI-powered medical imaging, centralized imaging services, cloud-based clinical imaging platforms, and Blinded Independent Central Review (BICR).
6. Which region holds a prominent position in the Clinical Trial Imaging Market?
North America holds a prominent position due to advanced clinical research infrastructure, pharmaceutical investments, and increasing demand for clinical trial imaging CRO services.
7. Who are the leading companies in the Clinical Trial Imaging Market?
Key Clinical Trial Imaging Market players include Clario, ICON plc, IQVIA, Medpace, Parexel, IXICO, Median Technologies, and Imaging Endpoints.